Flotetuzumab is a bispecific antibody targeting CD123 and CD3. It can simultaneously recognize the CD123 antigen on the surface of tumor cells and the CD3 molecule on the surface of effector T cells, thereby activating T cell function and triggering T cell-mediated targeted killing. It shows significant antitumor inhibitory activity in patient-derived xenograft (PDX) mouse models of acute myeloid leukemia (AML).
Purity:
95.00%
CAS Number:
[1664355-28-5]
Target:
Integrin|||Immunology/Inflammation related
* VAT and and shipping costs not included. Errors and price changes excepted